DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN ACROSS THE SPECTRUM OF KIDNEY FUNCTION: PATIENT-LEVEL NETWORK META-ANALYSES FROM COMBINE AF

Josephine Harrington, MD; Anthony P. Carnicelli, MD; Kaiyuan Hua, MS; Lars Wallentin, MD, PhD; Manesh R. Patel, MD; Stefan H. Hohnloser, MD; Robert P. Giugliano, MD, ScM; Keith A.A. Fox, MB, ChB; Ziad Hijazi, MD, MPH; Renato D. Lopes, MD, MHS, PhD; Sean

The research addresses the uncertainty surrounding the use of DOACs in patients with kidney dysfunction. It utilizes a patient-level network meta-analysis to compare outcomes such as stroke, major bleeding, and death among patients treated with standard-dose and lower-dose DOACs versus warfarin. The findings suggest that lower-dose DOACs may have a lower hazard of bleeding compared to warfarin, although they also present a higher risk of death in patients with worsening kidney function.